Congenica is the provider of the diagnostic decision support platform, Sapientia, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants. Congenica aims to revolutionize personalized patient care through accurate diagnoses, curation of evolving knowledgebases, and support in clinical trials and drug development.
80% of rare diseases are thought to have a genetic component, and patients wait an average of 4.7 years, and typically see 7.3 different clinical specialists1, before getting a diagnosis. Genome sequencing and variant interpretation facilitate speedier diagnoses and better clinical management and support.
Sapientia is intuitive to use, supporting the routine diagnostic workflow whilst enabling clinicians to progress through cases more quickly, optimizing throughput of patients and improving numbers of patients who can receive a diagnosis.
A diagnosis removes the fear of the unknown, allowing a patient’s family to deal with the known and make informed decisions. There is also the potential for healthcare savings by avoiding unnecessary appointments, tests and interventions.
Headquartered in Cambridge, UK, and with a footprint in the US and China, Congenica is born out of pioneering research from the Wellcome Trust Sanger Institute and the NHS. Congenica is a partner for the pivotal Genomics England 100,000 Genomes Project as well as China’s 100K Wellness Pioneer Project.